Bayer's Dr Schneider Emphasizes R&D Commitment
Aplanned record investment in R&D of 3.7 billion Deutschemarks ($2.2billion) by Bayer in 1997 is a sign of the German firm's commitment to R&D, according to its chairman Manfred Schneider. He said that 2.5 billion marks of the total will be directed towards life sciences - its health care and agriculture segments.
"We are committed to innovation because our goal is to become the leading integrated chemical and pharmaceutical company in the world," he said at Bayer's Perspective on Innovation 97 conference in Germany.
He talked of the company's "well-stocked" product pipeline, especially in pharmaceuticals, referring to the firm's septic shock treatment BAYX1351, for which Bayer is seeking approval (Marketletter March 3). He said this is the second genetically-engineered product the company has developed, the first being recombinant Factor VIII.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze